The cell and gene therapy CDMO market is experiencing significant growth, driven by the increasing number of cell and gene therapy candidates advancing through clinical development and commercialization. Rising investments in regenerative medicine, CAR-T therapies, gene editing technologies, and rare disease treatments are fueling demand for specialized manufacturing services. Pharmaceutical and biotechnology companies are increasingly partnering with CDMOs to access advanced manufacturing capabilities, reduce production costs, and accelerate time-to-market. Additionally, ongoing technological advancements in viral vector production, cell processing, and scalable manufacturing platforms are further supporting market expansion. As the CGT pipeline continues to mature globally, the need for experienced CDMO partners is expected to grow substantially over the coming years.
The cell and gene therapy CDMO market is experiencing significant growth, driven by the increasing number of cell and gene therapy candidates advancing through clinical development and commercialization. Rising investments in regenerative medicine, CAR-T therapies, gene editing technologies, and rare disease treatments are fueling demand for specialized manufacturing services. Pharmaceutical and biotechnology companies are increasingly partnering with CDMOs to access advanced manufacturing capabilities, reduce production costs, and accelerate time-to-market. Additionally, ongoing technological advancements in viral vector production, cell processing, and scalable manufacturing platforms are further supporting market expansion. As the CGT pipeline continues to mature globally, the need for experienced CDMO partners is expected to grow substantially over the coming years.